부산대학교 도서관

Objectives To review systematically all the available evidence on efficacy and safety of cannabinoids for treating neurogenic lower urinary tract dysfunction ( NLUTD) in patients with multiple sclerosis ( MS). Patients and Methods The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA) statement. Studies were identified by electronic search of the Cochrane register, Embase, Medline, Scopus (last search on 11 November 2016). Results After screening 8 469 articles, we included two randomized controlled trials and one open-label study, in which a total of 426 patients were enrolled. Cannabinoids relevantly decreased the number of incontinence episodes in all three studies. Pooling data showed the mean difference in incontinence episodes per 24 h to be −0.35 (95% confidence interval −0.46 to −0.24). Mild adverse events were frequent (38-100%), but only two patients (0.7%) reported a serious adverse event. Conclusions Preliminary data imply that cannabinoids might be an effective and safe treatment option for NLUTD in patients with MS; however, the evidence base is poor and more high-quality, well-designed and adequately powered and sampled studies are urgently needed to reach definitive conclusions. [ABSTRACT FROM AUTHOR]